Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

Tracking Information
First Submitted Date	December 19, 2006
First Posted Date	December 20, 2006
Last Update Posted Date	December 20, 2006
Study Start Date	Not Provided
Primary Completion Date	Not Provided
Current Primary Outcome Measures	Not Provided
Original Primary Outcome Measures	Not Provided
Change History	No Changes Posted
Current Secondary Outcome Measures	Not Provided
Original Secondary Outcome Measures	Not Provided
Current Other Outcome Measures	Not Provided
Original Other Outcome Measures	Not Provided
Descriptive Information
Brief Title	Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes
Official Title	Not Provided
Brief Summary	The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.
Detailed Description	Not Provided
Study Type	Observational
Study Design	Time Perspective: Longitudinal; Time Perspective: Prospective
Target Follow-Up Duration	Not Provided
Biospecimen	Not Provided
Sampling Method	Not Provided
Study Population	Not Provided
Condition	Healthy
Intervention	Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)
Study Groups/Cohorts	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status	Completed
Enrollment; (submitted: December 19, 2006)	20
Original Enrollment	Same as current
Study Completion Date	Not Provided
Primary Completion Date	Not Provided
Eligibility Criteria	Inclusion Criteria: Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better. Exclusion Criteria: Patients not meeting above stated age criteria; Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study); History of serious ocular, neurological, cardiovascular disease; History of severe systemic disease; History of arrhythmias or high blood pressure; Patients currently taking any type of ocular or systemic medications except multivitamins.; Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.
Sex/Gender	Sexes Eligible for Study: All
Ages	18 Years to 50 Years (Adult)
Accepts Healthy Volunteers	Yes
Contacts	Contact information is only displayed when the study is recruiting subjects
Listed Location Countries	United States
Removed Location Countries
Administrative Information
NCT Number	NCT00413751
Other Study ID Numbers	WRAMC WU #03-23004
Has Data Monitoring Committee	Not Provided
U.S. FDA-regulated Product	Not Provided
IPD Sharing Statement	Not Provided
Responsible Party	Not Provided
Study Sponsor	Walter Reed Army Medical Center
Collaborators	Not Provided
Investigators	Principal Investigator: KRAIG S. BOWER, MD Walter Reed Army Medical Center
PRS Account	Walter Reed Army Medical Center
Verification Date	December 2006